The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells
Abstract
This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 mu M (IC50 0.68 +/- 0.04 mu M, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 mu M), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. [GRAPHICS] .
Keywords:
the avarol scaffold / Dysidea avara / Brain tumoursSource:
Natural Product Research, 2018, 32, 5, 616-620Publisher:
- Taylor & Francis Ltd, Abingdon
Funding / projects:
- Synthesis and biological testing of new mimics or derivatives of selected cytotoxic lactones, antitumor agent tiazofurin and natural naphthenic acids (RS-172006)
- Natural products of wild, cultivated and edible plants: structure and bioactivity determination (RS-172053)
DOI: 10.1080/14786419.2017.1327959
ISSN: 1478-6419
PubMed: 28504009
WoS: 000426941200021
Scopus: 2-s2.0-85019215056
Collections
Institution/Community
Institut za multidisciplinarna istraživanjaTY - JOUR AU - Pejin, Boris AU - Tommonaro, Giuseppina AU - Glumac, Miodrag AU - Jakimov, Dimitar AU - Kojić, Vesna PY - 2018 UR - http://rimsi.imsi.bg.ac.rs/handle/123456789/1194 AB - This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 mu M (IC50 0.68 +/- 0.04 mu M, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 mu M), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. [GRAPHICS] . PB - Taylor & Francis Ltd, Abingdon T2 - Natural Product Research T1 - The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells EP - 620 IS - 5 SP - 616 VL - 32 DO - 10.1080/14786419.2017.1327959 ER -
@article{ author = "Pejin, Boris and Tommonaro, Giuseppina and Glumac, Miodrag and Jakimov, Dimitar and Kojić, Vesna", year = "2018", abstract = "This study aimed to screen in vitro antitumour activity of the redox couple avarol/avarone against the human malignant glioma cell line U-251 MG for the first time. Compared both with avarol and positive controls used (temozolomide and doxorubicin), avarone was found to be the most active compound with IC50 value below 1 mu M (IC50 0.68 +/- 0.04 mu M, 96 h). Considerable less DNA damage in the cells treated with avarol and avarone vs. doxorubicin (105 & 123% vs. 299%, respectively; untreated U-251 MG cells were used as a control, 100%), coupled with no sign of cytotoxicity against the normal human foetal lung fibroblast MRC-5 cells (IC50 > 100 mu M), has actually pointed out the importance of this marine sesquiterpenoid quinone structure as a promising lead compound in development of novel brain chemotherapeutics. [GRAPHICS] .", publisher = "Taylor & Francis Ltd, Abingdon", journal = "Natural Product Research", title = "The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells", pages = "620-616", number = "5", volume = "32", doi = "10.1080/14786419.2017.1327959" }
Pejin, B., Tommonaro, G., Glumac, M., Jakimov, D.,& Kojić, V.. (2018). The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. in Natural Product Research Taylor & Francis Ltd, Abingdon., 32(5), 616-620. https://doi.org/10.1080/14786419.2017.1327959
Pejin B, Tommonaro G, Glumac M, Jakimov D, Kojić V. The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells. in Natural Product Research. 2018;32(5):616-620. doi:10.1080/14786419.2017.1327959 .
Pejin, Boris, Tommonaro, Giuseppina, Glumac, Miodrag, Jakimov, Dimitar, Kojić, Vesna, "The redox couple avarol/avarone in the fight with malignant gliomas: the case study of U-251 MG cells" in Natural Product Research, 32, no. 5 (2018):616-620, https://doi.org/10.1080/14786419.2017.1327959 . .